Patent US4035832A successfully refreshed from Google Patents.
Patent US5114721A successfully refreshed from Google Patents.
US5114721A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Preparation of t-cell and t-cell membrane for use in prevention and treatment of autoimmune diseases
Assignee: Yeda Research and Development Co Ltd
•
Filing: 1989-03-15
•
Granted: 1992-05-19
•
Expires: 2009-03-15
Abstract
Abstract Pharmaceutical preparations are provided for preventing or treating autoimmune diseases in which the active principle is activated T-lymphocyte cells, specific for the autoimmune disease to be treated, which cells have been treated by incubation with a photoactivatable psoralen cross-linking agent, such as 8-methoxypsoralen, and then photoactivated. The active principle may also be the membrane fraction of such cells. Such preparations may be formulated into pharmaceutical compositions and administered to prevent or treat autoimmune diseases.
Inventors
- 👤 Irun R. Cohen
- 👤 Meir Shinitzky
- 👤 Richard L. Edelson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 22:03
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/0005; A61K39/0008; A61P; A61P37/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
116 words
A preparation for preventing or treating an autoimmune disease, consisting essentially of T-lymphocyte cells specific for the autoimmune disease, which cells have been activated by having been exposed to an antigen specific for the autoimmune disease or a mitogen capable of inducing an immune response by the T-lymphocyte cells, and which cells have been further treated by contacting said cells with a photoactivatable psoralen cross-linking agent which is selective for a receptor on the cell membrane, said cross-linking agent having been present in an amount sufficient to cause cross-linking to occur on the surface of said cells upon photoactivation, followed by photoactivation of the psoralen cross-linking agent; or cell membranes separated from said treated T-lymphocyte cells.
Claim 2
Dependent Claim
116 words
A preparation for preventing or treating an autoimmune disease, consisting essentially of T-lymphocyte cells specific for the autoimmune disease, which cells have been activated by having been exposed to an antigen specific for the autoimmune disease or a mitogen capable of inducing an immune response by the T-lymphocyte cells, and which cells have been further treated by contacting said cells with a photoactivatable psoralen cross-linking agent which is selective for a receptor on the cell membrane, said cross-linking agent having been present in an amount sufficient to cause cross-linking to occur on the surface of said cells upon photoactivation, followed by photoactivation of the psoralen cross-linking agent; or cell membranes separated from said treated T-lymphocyte cells.
Claim 3
Dependent Claim
30 words
A preparation in accordance with claim 1, wherein the cross-linking agent is selected from the group consisting of psoralen, 8-methoxypsoralen, 4, 5',8-trimethylpsoralen, 4',5'-dihydropsoralen, 3-carbethoxypsoralen, 4',5'-dihydro 3-carbethoxypsoralen, 5-methoxypsoralen, 4'-(hydroxymethyl)-4,5',8-trimethylpsoralen, and aminomethyltrioxypsoralen.
Claim 4
Dependent Claim
13 words
A preparation in accordance with claim 1, wherein the cross-linking agent is 8-methoxypsoralen.
Claim 5
Dependent Claim
38 words
A preparation in accordance with claim 1, wherein said T-lymphocyte cells are specific for an autoimmune disease selected from the group consisting of multiple sclerosis, thyroiditis, diabetes type I, ankylosing spondylitis, rheumatoid arthritis, myasthenia gravis, and anterior uveitis.
Claim 6
Dependent Claim
17 words
A preparation in accordance with claim 1, wherein said preparation consists essentially of whole treated T-lymphocyte cells.
Claim 7
Dependent Claim
22 words
A preparation in accordance with claim 1, wherein said preparation consists essentially of the cell membranes separated from said treated T-lymphocyte cells.
Claim 8
Independent Claim
102 words
A method for producing cross-linked activated T-lymphocytes, comprising the steps of: suspending T-lymphocyte cells specific for an autoimmune disease, which cells have been activated by having been exposed to an antigen specific for the autoimmune disease or a mitogen capable of inducing an immune response by the T-lymphocyte cells, in a buffer; contacting the suspended cells with a photoactivatable psoralen cross-linking agent which is selective for a receptor on the cell membrane of said cells, in an amount sufficient to cause cross-linking to occur on the cell membrane upon photoactivation; and photoactivating the psoralen cross-linking agent with light of an appropriate wavelength.
Claim 9
Independent Claim
102 words
A method for producing cross-linked activated T-lymphocytes, comprising the steps of: suspending T-lymphocyte cells specific for an autoimmune disease, which cells have been activated by having been exposed to an antigen specific for the autoimmune disease or a mitogen capable of inducing an immune response by the T-lymphocyte cells, in a buffer; contacting the suspended cells with a photoactivatable psoralen cross-linking agent which is selective for a receptor on the cell membrane of said cells, in an amount sufficient to cause cross-linking to occur on the cell membrane upon photoactivation; and photoactivating the psoralen cross-linking agent with light of an appropriate wavelength.
Claim 10
Dependent Claim
23 words
A method in accordance with claim 7, wherein the photoactivatable psoralen is -b 8-methoxypsoralen and the light of an appropriate wavelength is UVA.
Claim 11
Dependent Claim
27 words
A pharmaceutical composition for preventing or treating an autoimmune disease, comprising an effective amount of a preparation in accordance with claim 1 in a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
28 words
A method for preventing or treating a specific autoimmune disease in a patient, comprising administering to said patient an effective quantity of a composition according to claim 9.
Claim 13
Dependent Claim
32 words
A method for treating a specific autoimmune disease in a patient afflicted with said autoimmune disease comprising administering to said patient an effective amount of a composition in accordance with claim 9.
Claim 14
Dependent Claim
41 words
A method in accordance with claim 11, wherein said T-lymphocyte cells treated with said photoactivatable cross-linking agent are T-lymphocyte cells removed from said patient which have been exposed to a mitogen capable of inducing an immune response by the T-lymphocyte cells.
Claim 15
Dependent Claim
20 words
A preparation in accordance with claim 1, wherein said receptor is the 22 kD cell surface receptor which recognizes 8-methoxypsoralen.
Claim 16
Dependent Claim
66 words
A preparation in accordance with claim 1, wherein said treatment with psoralen cross-linking agent comprises contacting about 5-10×10 6 /ml of said cells, suspended in tissue culture medium, with about 50 to about 500 μg/ml of said psoralen cross-linking agent and subjecting said cells to light of suitable wavelength to cause cross-linking of said psoralen for a period of from about 5 to about 60 minutes.
Claim 17
Dependent Claim
52 words
A method in accordance with claim 7 wherein said suspending step comprises suspending about 5-10×10 6 /ml of said psoralen cross-linking agent and said photoactivating step comprises subjecting said cells to light of suitable wavelength to cause cross-linking of said psoralen for a period of from about 5 to about 60 minutes.
Claim 18
Dependent Claim
33 words
A method in accordance with claim 10 wherein said autoimmune disease is selected from the group consisting of multiple sclerosis, thyroiditis, diabetes type I, ankylosing spondylitis, rheumatoid arthritis, myasthenia gravis, and anterior uveitis.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-05-19 | 1995-11-18 | 1996-05-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-05-19 | 1999-11-18 | 2000-05-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-05-19 | 2003-11-18 | 2004-05-19 | $7700.00 | Window Closed / Lapsed |